Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Middle East Conflict Impacts Australia and New Zealand Businesses 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
CHARLESTON, S.C., May 01, 2018 -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) will announce its first quarter 2018 financial and operating results after market close on Monday, May 7, 2018. The Company will host a conference call to discuss these results on Tuesday, May 8, 2018 at 8:30 a.m. Eastern Time.
Participants may access the conference call by telephone using the following numbers:
- Toll-Free: 877-407-8029, Confirmation #13679691
- Toll: 201-689-8029, Confirmation #13679691
A replay will also be available on the Company’s website for a period of 30 days.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a specialty biopharmaceutical company focused on developing and commercializing, principally through out-licensing arrangements, Macrilen™ (macimorelin), an orally available ghrelin agonist, to be used in the diagnosis of patients with adult growth hormone deficiency. Aeterna Zentaris has entered into a license and assignment agreement with a wholly-owned subsidiary of Strongbridge Biopharma plc to carry out development, manufacturing, registration and commercialization of Macrilen™ (macimorelin) in the United States and Canada. For more information, visit www.aezsinc.com.
Contact:
Aeterna Zentaris Inc.
James Clavijo
Chief Financial Officer
[email protected]
843-900-3201
